BioSpace News Archive

Calliditas Therapeutics AB announced that the United States Patent and Trademark Office has issued a patent for application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer.”.

China Medical System Holdings Limited is pleased to announce that on 11 June 2024, the New Drug Application of the Group’s innovative drug methylthioninium chloride enteric-coated sustained-release tablets has been approved by the National Medical Products Administration of China.

KalVista Pharmaceuticals, Inc., announced the submission of a New Drug Application for U.S. Food and Drug Administration review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema attacks in adults and pediatric patients aged 12 years and older.

Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) today announces randomization of the first patient in the PRISM-MEL-301 trial, assessing the efficacy and safety of brenetafusp (IMC-F106C; PRAME-A02), in combination with nivolumab, in first-line advanced or metastatic cutaneous melanoma.

Emergex Vaccines Holding Limited announced that Emergex has received its Manufacturing and Import Authorisation Investigational Medicinal Product from the UK’s Medicines and Healthcare Products Regulatory Agency to advance its novel T cell-priming vaccine candidates into clinical production.

NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with severe neuromuscular diseases, today announces that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial, named SYNAPSE-CMT, of NMD670 in patients living with Charcot-Marie-Tooth (CMT) type 1 and type 2 disease.

Belharra Therapeutics, a next-generation chemoproteomics company transforming small molecule drug discovery by illuminating binding pockets on elusive, high-value drug targets across the proteome, today announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases.

LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, is pleased to announce the completion of the acquisition of Virage Santé, a company specializing in the manufacturing and marketing of natural health products, based in Lévis, Quebec.

EyePoint Pharmaceuticals, Inc. today announced that the Company will host an R&D Day on Wednesday, June 26, 2024 from 8:00 a.m. to 9:30 a.m. ET.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc. presented new long-term CNM-Au8 treatment results for survival and neurofilament light levels from the HEALEY ALS Platform Trial open label extension at the European Network for the Cure of ALS meeting in Stockholm, Sweden.